<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506402</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-104</org_study_id>
    <nct_id>NCT00506402</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CASI Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CASI Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The main objectives of this study are to evaluate the side effects of MKC-1 and to determine&#xD;
      a safe dose of MKC-1 for future studies in patients with hematological malignancies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of treatment emergent adverse events</measure>
    <time_frame>Throughout study treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hematological Malignancies</condition>
  <condition>Myelodysplasia</condition>
  <condition>Agnogenic Myeloid Metaplasia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MKC-1</intervention_name>
    <description>Capsule, 30 mg and 100 mg, BID, continuous dosing</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have relapsed/refractory leukemias for which no standard therapies are&#xD;
             anticipated to result in a durable remission. Patients with poor-risk myelodysplasia&#xD;
             (MDS) [i.e. IPSS â‰¥ 1.5 or chronic myelomonocytic leukemia (CMML) are also candidates&#xD;
             for this protocol. Relapsed/refractory leukemias include acute non-lymphocytic&#xD;
             leukemia (AML) by WHO classification, acute lymphocytic leukemia (ALL), chronic&#xD;
             lymphocytic leukemia (CLL), or chronic myelogenous leukemia (CML) in blast crisis.&#xD;
             Patients with agnogenic myeloid metaplasia (AMM) are also eligible.&#xD;
&#xD;
          2. Age &gt; 18 years.&#xD;
&#xD;
          3. ECOG performance status of 0-2.&#xD;
&#xD;
          4. In the absence of rapidly progressing disease, the interval from prior treatment to&#xD;
             time of study drug administration should be at least 2 weeks for cytotoxic agents, or&#xD;
             at least 5 half-lives for noncytotoxic agents. If the patient is on hydroxyurea to&#xD;
             control peripheral blood leukemic cell counts, the patient must be off hydroxyurea for&#xD;
             at least 48 hours before initiation of treatment on this protocol.&#xD;
&#xD;
          5. Persistent clinically significant chronic toxicities from prior chemotherapy, surgery&#xD;
             or radiotherapy must have resolved to NCI CTCAE Grade &lt; 1, except for alopecia.&#xD;
&#xD;
          6. The following laboratory results, within 10 days of MKC-1 administration (unless the&#xD;
             abnormality is considered attributable to leukemia):&#xD;
&#xD;
               -  Serum creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
               -  Total bilirubin &lt; ULN (unless a diagnosis of Gilbert's disease is present)&#xD;
&#xD;
               -  AST &lt; 2.5 x ULN (upper limit of normal)&#xD;
&#xD;
               -  Serum albumin &gt; 3.0 g/dL&#xD;
&#xD;
          7. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-existing hepatomegaly with disease measured as &gt; 2 cm below the costal margin,&#xD;
             secondary to malignancy.&#xD;
&#xD;
          2. Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically&#xD;
             sterile or they must agree to use a physical method of contraception. Female patient&#xD;
             with childbearing potential must have a negative pregnancy test within the 10 days&#xD;
             before the first MKC-1 administration. Male patients must be surgically sterile or&#xD;
             agree to use an acceptable method of contraception. Pregnant and nursing patients are&#xD;
             excluded because the effects of MKC-1 on a fetus or nursing child are unknown.&#xD;
&#xD;
          3. Clinical evidence of bowel obstruction, active uncontrolled malabsorption syndromes or&#xD;
             a history of total gastrectomy.&#xD;
&#xD;
          4. Impaired cardiac function including myocardial infarction within previous 3 months,&#xD;
             symptomatic coronary artery disease, arrhythmias not controlled by medication, or&#xD;
             uncontrolled congestive heart failure.&#xD;
&#xD;
          5. Patients receiving any other standard or investigational cytotoxic treatment for their&#xD;
             hematologic malignancy.&#xD;
&#xD;
          6. Treatment with antiretroviral therapy metabolized through CYP3A4 (including indinavir,&#xD;
             nelfinavir, ritonavir and saquinavir) due to the potential for drug interactions wth&#xD;
             MKC-1.&#xD;
&#xD;
          7. Any medical conditions that, in the investigator's opinion, would impose excessive&#xD;
             risk to the patient. Examples of such conditions include congestive heart failure of&#xD;
             Class III or IV of the NYHA classification, active infection, or any psychiatric&#xD;
             condition that would interfere with the understanding of the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Yee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>July 24, 2007</study_first_submitted>
  <study_first_submitted_qc>July 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <last_update_submitted>May 4, 2009</last_update_submitted>
  <last_update_submitted_qc>May 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>EntreMed, Inc.</organization>
  </responsible_party>
  <keyword>Adult patients with refractory leukemias, MDS or AMM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

